



Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website : www.fermentabiotech.com



December 10, 2025

To
Corporate Relations,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort – 400001

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Ref: Scrip Code 506414

We are pleased to inform you that, in continuation to our earlier intimation dated December 7, 2025, the Board of Directors of the Company, at its meeting held today i.e. on December 10, 2025, has, *inter alia*, considered and approved the proposal for raising of funds either by way of issuance of equity shares and/or other securities including securities convertible into equity shares, warrants or fully convertible debentures, partly convertible debentures, non-convertible debentures along with warrants, or convertible preference shares (collectively "Securities"), for an aggregate amount not exceeding Rs. 150 Crores (Rupees One Hundred and Fifty Crores only), by way of public issue, rights issue, preferential allotment, private placement, including Qualified Institutions Placement(s) ('QIP') in one or more tranches or any other mode or combination thereof as may be permitted under applicable laws, such regulatory/statutory approvals as may be required, and subject to approval of shareholders of the Company, which will be sought separately at the appropriate time.

The information required as per Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 ("Master Circular") is enclosed herewith as Annexure A.



Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website : www.fermentabiotech.com



The Board meeting commenced at 11:30 a.m. (IST) and concluded at 2:50 p.m. (IST). Kindly take the above information on record.

Thanking you,

Yours faithfully,

For **Fermenta Biotech Limited**

Varadvinayak Khambete

Company Secretary and Legal - Head

Membership No. A33861

Encl: (1) Annexure A

Annexure A
(Information w.r.t. raising of funds)

**Detailed disclosure under Regulation 30 read with Schedule III of Listing Regulations
and Master Circular**

Sr.	Particulars	Disclosure
a.	type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Equity Shares and/or other securities including securities convertible into equity shares, warrants or fully convertible debentures, partly convertible debentures, non-convertible debentures along with warrants, or convertible preference shares (collectively "Securities") or any combination thereof, in accordance with applicable law, in one or more tranches.
b.	type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.);	Public issue, rights issue, preferential allotment, private placement, including Qualified Institutions Placement(s) ('QIP') in one or more tranches or any other mode or combination thereof as may be decided by the Board of Directors, subject to compliance with applicable laws.
c.	total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Up to an aggregate amount not exceeding Rs. 150 Crores or an equivalent amount thereof at such price or prices (inclusive of such premium as may be fixed on such securities) as may be permissible under applicable law.
d.	in case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s): (i) names of the investors;	Not applicable

	(ii) post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors; (iii) in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	
e.	in case of bonus issue the listed entity shall disclose the following additional details to the stock exchange(s): (i) whether bonus is out of free reserves created out of profits or share premium account; (ii) bonus ratio; (iii) details of share capital - pre and post bonus issue; (iv) free reserves and/ or share premium required for implementing the bonus issue; (v) free reserves and/ or share premium available for capitalization and the date as on which such balance is available; (vi) whether the aforesaid figures are audited; vii. estimated date by which such bonus shares would be credited/dispatched	Not applicable
f.	in case of issuance of depository receipts (ADR/GDR) or FCCB the listed entity shall disclose following additional details to the stock exchange(s): (i) name of the stock exchange(s) where ADR/GDR/FCCBs are listed (opening – closing status) / proposed to be listed; (ii) proposed no. of equity shares underlying the ADR/GDR or on conversion of FCCBs; (iii) proposed date of allotment, tenure, date of maturity and coupon offered, if any of FCCB's; (iv) issue price of ADR/GDR/FCCBs (in terms of USD and in INR after considering conversion rate); (v) change in terms of FCCBs, if any; (vi) details of defaults, if any, by the listed entity in payment of coupon on FCCBs & subsequent	Not applicable

	updates in relation to the default, including the details of the corrective measures undertaken (if any);	
g.	<p>in case of issuance of debt securities or other non-convertible securities the listed entity shall disclose following additional details to the stock exchange(s):</p> <p>(i) size of the issue;</p> <p>(ii) whether proposed to be listed? If yes, name of the stock exchange(s);</p> <p>(iii) tenure of the instrument - date of allotment and date of maturity;</p> <p>(iv) coupon/interest offered, schedule of payment of coupon/interest and principal;</p> <p>(v) charge/security, if any, created over the assets;</p> <p>(vi) special right/interest/privileges attached to the instrument and changes thereof;</p> <p>(vii) delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal;</p> <p>(viii) details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any;</p> <p>(ix) details of redemption of preference shares indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures</p>	Not applicable
h.	any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not applicable.
